neuropsychiatric disorders
- Business
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
Ingelheim, Germany & Baltimore, Maryland, United States: Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical…
Read More »